Podcasts about jacksonville

Do you need a miracle? In Matthew 8, Jesus meets people in their deepest places of need and demonstrates His authority over sickness, brokenness and darkness. Through these encounters, we see that faith is not about having all the answers— it's about trusting the One who does. No matter what you are facing, Jesus invites you to come to Him with humility, bold faith and full surrender. He is still the Great Physician, the Prince of Peace and the One who makes all things new. If the tomb is empty, anything is possible.

Dr. Monty Pal and Dr. Vamsi Velcheti discuss the evolving treatment landscape in EGFR-mutated non-small cell lung cancer, including landmark trials like FLAURA2, novel drug therapies, and the growing importance of ctDNA and MRD testing. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today, I'm truly delighted to introduce Dr. Vamsi Velcheti, who's a professor of medicine and the chief of hematology-oncology at the Mayo Clinic in Jacksonville, Florida. We'll be discussing the expanding treatment landscape in EGFR-positive lung cancer and how to navigate the challenges of balancing treatment efficacy, toxicity, and patient quality of life in the EGFR-positive space.  Just FYI, our full disclosures are available in the transcript of this episode.  Vamsi, it's so great to have you on the podcast. Thank you so much for being here. Dr. Vamsi Velcheti: Thank you, Monty. It's a pleasure to be here with you. It's a really exciting topic and there are a lot of updates in the EGFR space. Dr. Monty Pal: So, I'm going to need your help with this because I'll be honest with you, I see very little lung cancer, if any, in my practice. I'm pretty much exclusively kidney cancer these days. I'm coming on 20 years at City of Hope now, and I still remember when trials like ECOG 1599 were presented with, you know, platinum doublets. And, of course, the field has changed a lot since then. But tell us a little bit about the first-line landscape, and I think just for the sake of time, we're going to stick with EGFR-positive disease here. What does it look like these days? Dr. Vamsi Velcheti: Monty, the foundation of care remains the third-generation EGFR inhibitors. These are selective EGFR inhibitors, like osimertinib. We've had an evolution of the development of these TKIs. Like, you know, we had the first-generation, second-generation, not-so-selective EGFR inhibitors. Now we have mutant-selective EGFR inhibitors in the clinic, and they're doing a really good job. And these are quite effective in patients who have classical activating mutations. But the reality is that these have not been transformative. These agents have fundamentally changed the response patterns, excellent CNS penetration, and very good tolerability profile. However, we don't see a lot of durability in terms of the response. So, what's different today is now there have been several trials in combination with these third-generation EGFR inhibitors that have really laid the foundation of how we kind of think about EGFR-positive disease. At the high level, there are a lot of challenges to selecting the patients for these combination-based modalities. I'm assuming we'll be talking more about these different trials and different approaches. Some of these combination-based strategies have really moved the needle in terms of improving overall survival and really improving long-term outcomes and durability in our patients. Dr. Monty Pal: And we are going to get into the weeds on this in just a moment. But I did kick off this podcast talking about chemotherapy, ECOG 1599. It does seem as though chemotherapy is still a component of management in advanced non-small cell lung cancer. So, can you tell us about, perhaps first, you mentioned osimertinib, you know, some of these next-generation EGFR inhibitors. Tell us about the role of chemo plus osimertinib. Dr. Vamsi Velcheti: That's exactly where I was going with the combination-based strategies. You know, we first started off with our earlier trials in the EGFR space evaluating the question of, are targeted therapies, are these highly effective, third-generation, EGFR-selective inhibitors, superior to platinum-doublet chemotherapy? And we've had multiple trials demonstrating that, like the FLAURA trial and in the past with second-generation EGFR inhibitors like erlotinib and gefitinib and afatinib. So, we know that these TKIs actually perform better than platinum-doublet chemotherapy. Now, we have a large, global, phase 3 trial data from the FLAURA2 trial, which looks at the question, "Hey, you know, osimertinib is better than chemotherapy, platinum-doublet chemotherapy. Can we do even better by combining osimertinib with platinum-doublet chemotherapy?" So, FLAURA2 answered that question. This is a large, phase 3 trial, and it's a positive trial with improved durability of disease control and improving overall survival with combination with chemotherapy. So, it's a very important and landmark trial, and essentially combining osimertinib with a platinum-based chemotherapy improved responses, deepened responses, and improved overall survival and really changing the disease trajectory. And this strategy is definitely compelling, especially in patients who have certain clinical high-risk features like, you know, patients who have high disease burden or patients who are sometimes having rapid disease progression early on osimertinib, especially with patients who have a lot of visceral disease burden. So, intensifying treatments up front could alter the natural trajectory of the disease. Dr. Monty Pal: So, you sort of alluded to this in that last part there, but is that kind of how you in clinical practice select? Is it based on, you know, visceral involvement? Is it based on rapidity of disease where you think about adding chemotherapy to osimertinib? Maybe you can give us the corollary. Which patients do you just use osimertinib alone in, for instance? Dr. Vamsi Velcheti: Definitely, there are some patients who have low disease burden and they have the classical mutations, like an exon 19 deletion. And these patients, especially if they don't have a lot of disease burden, they don't have CNS involvement, there may be a subset of patients who could just do fine on osimertinib of course, with close monitoring of the disease. I guess we'll get into that later, how do we do that with either ctDNA or like closer imaging or both. So, there may be some opportunity to kind of escalate patients' treatments based on certain clinical characteristics or radiographic characteristics or certain biological characteristics informed by ctDNA or other approaches. Dr. Monty Pal: No, that's interesting. And you're right, we will chat about ctDNA in just a bit. But before we get there, I think one of the big agents that has really sort of come to the fore in advanced non-small cell lung cancer is amivantamab. I've heard a lot about this in the context of even kidney cancer because in certain subsets, I'm interested in MET-directed therapies and so forth, right? So maybe tell us a little bit about the mechanism of amivantamab first, and then maybe tell us about this pivotal MARIPOSA trial where it's combined with lazertinib. Dr. Vamsi Velcheti: So, the MARIPOSA trial compared lazertinib alone with amivantamab plus lazertinib. And this trial demonstrated overall survival advantage, and there were key differences in terms of tolerability and the safety of amivantamab, which is an EGFR and MET bispecific, and there were certain kind of unique toxicity profiles that make it a little different than the intensification approach with chemotherapy through the FLAURA2 trial. So, there's a trade-off in terms of the toxicity profile. It's a different agent and a different management protocol in terms of dermatological toxicity management that clinicians need to be comfortable with. And also, there are certain unique issues in terms of amivantamab; there's a higher rate of infusion-related reactions, there's an increased risk for edema and VTEs because of amivantamab. Certainly a different toxicity profile, different management paradigm there in terms of longitudinal care of these patients requiring dermatological care and like, you know, close monitoring and prophylaxis VTEs. But having said that, definitely it's a different strategy, and it kind of changes the biology and the natural history of the cancers, and we do see some durability of responses that we see with the MARIPOSA. So, it's certainly a great alternative, at least for some patients. Dr. Monty Pal: That was a great overview of MARIPOSA. Now comes the really difficult question, which is, how do you choose between the two? You have these two great options, right, for EGFR-positive patients. You've already highlighted some of the distinctions in terms of toxicity. I think the audience is well aware of the side effects of chemo-doublet, perhaps even the EGFR-based therapies. Amivantamab is quite new. Give us a sense of how you in clinical practice decide between the two potential options here. Dr. Vamsi Velcheti: Yeah, I think that's the big challenge. I think these are two independent strategies that have evolved through the phase 3, and both of them have demonstrated overall survival benefit. So, the way I think about this is in three dimensions, right? Like, the disease biology, the patient priorities, and feasibility of care delivery. So, when I talk about the disease biology, you know, the mechanism is very different, and MET is a very dominant driver of disease in EGFR-altered patients and it's a significant mechanism of resistance, acquired resistance to TKIs. So, certainly I think there's a patient population that could benefit from a MET-directed therapy up front. However, we don't have great data to kind of really demonstrate how using amivantamab in the front line is going to change that. And are there like perhaps like some patients who we could identify who would benefit from such a strategy? Very recently, there have been some approvals in the second-line setting in lung cancer, not in the EGFR space, but like in generally in lung cancer, with the MET ADCs, and those drugs are approved with a companion diagnostic, which requires MET IHC testing. So, what has happened, at least in large academic practices and also I think in the community now, they have been checking for MET IHC expression more routinely in lung cancer. What we have been doing in our institution is we have been doing MET IHC as a reflex for all patients with EGFR, not just EGFR, but all non-small cell lung cancer patients. What that has done is now, like, we have been increasingly testing patients with EGFR for MET. And there's clearly a subset of patients who have de novo MET expression and a high MET expression. And those patients, I've been kind of like preferentially treating them with the MARIPOSA regimen. But again, I have to caution the audience that we still don't have data that MET IHC is going to help us make those decisions, whether it's better than like a FLAURA2 regimen. But however, in the second-line setting in the CHRYSALIS trial, we know that MET is a very powerful predictor of response to amivantamab. We really need more data there, but that's what I have been doing in my practice. But also, there's a lot of patient preference here. Like, there are some patients who don't want chemotherapy, and they want a non-chemotherapy approach. So, certainly there are some patients who prefer to have amivantamab. And now with the amivantamab, the subcutaneous version, the infusion reactions and the logistics of actual administration of amivantamab are more favorable with the subcutaneous approval. So, those are some of the elements that we need to take into account. Dr. Monty Pal: Well, I want to hone in on that because this subcutaneous administration route has been a big debate that I've seen on social media. Tell us, how much easier does it actually make the amivantamab experience? Does it cut down on the rash? Is it just infusion reactions? What's been your clinical experience? Vamsi Velcheti, MD: So, the subcutaneous administration of amivantamab has definitely improved the infusion reaction issue. Very rarely patients have infusion reaction now with the subcutaneous injections. And also, the infusion time is much, much shorter. Like we don't need a lot of infusion time, which is sometimes a challenge in busy infusion clinics. We need to take that into account. As far as the impact of the subcutaneous formulation on dermatological toxicity, we haven't really seen significant difference in terms of the intensity or rates of dermatological toxicity with subcutaneous. The benefits are really with the infusion reaction, the ease of administration. And interestingly, in the PALOMA trial, it also seems to be, even though this was not the primary endpoint of the study, there seems to be some suggestion that the subcutaneous amivantamab seems to have improved OS compared to the IV amivantamab. We don't really understand why, but that's a finding from the trial that's very intriguing. Dr. Monty Pal: That is really fascinating. I'm kind of curious to see how that's going to pan out. I'm going to shift gears a little bit here. And, you know, as we sort of close, I wanted to talk a little bit about biomarkers. I mean, this is obviously not a lung cancer-specific issue. It's something we think about across the board. But what I will say is that there are certain commonalities, and in bladder cancer, we think a lot now about ctDNA. But you've been way ahead of the game in lung cancer. Tell us how you guys use ctDNA, maybe both from the standpoint of monitoring for mutational status, but if you can, maybe offer some insights into some of these new MRD tests that are available too. Dr. Vamsi Velcheti: Yeah, it's rapidly evolving. Certainly, I think in the lung cancer space, you know, this has really kicked off in the lung cancer space with incorporating ctDNA into the workflow. Of course, you know, like baseline evaluation, we still kind of heavily rely on tissue genomic sequencing. But as you know, with targeted therapy, a lot of these patients have disease that evolves over time, and changes in terms of mutational pattern driving acquired resistance is a major issue across different molecular subtypes. And especially so in EGFR, when there are certain actionable opportunities associated with that transformation. So, we need to kind of have like a longitudinal snapshot of how we monitor these patients. So, the ctDNA has come to be like a tool that has now come to the forefront of clinical workflow, and almost all my patients who are having disease progression have ctDNA for kind of evaluating for resistance and informing treatment decisions, especially in EGFR. But having said that, there are a lot of challenges in terms of using ctDNA as a tool for monitoring. There are a lot of different types of assays and different platforms, and being able to use this as a quantitative tool that would be used along with the CT scans that we routinely use in clinical practice has been a challenge. And I think I would love to hear your perspectives as well, Monty, about how you're thinking about that in bladder and other disease contexts. But having said that, I think there's a lot of opportunity to incorporate ctDNA and MRD assays into clinical decision-making. Right now, in terms of clinical trials and clinical development, there have been some very interesting trials that are currently ongoing, especially in the EGFR space. We know that patients who clear ctDNA, based on some retrospective data and also like some retrospective-prospective data from trials that have already read out, that patients who clear ctDNA early with target therapy tend to do much better. They have a longer durability of response. There may be a subset of patients who have, even though they're having radiographic response, they have persistent ctDNA after a certain time point of initiation of targeted therapy. Those patients may require escalation of therapy. We don't yet know. I can't recommend that as a standard right now because we don't have clinical evidence to support that. But however, some of the clinical trials, like the ELIOS trial that's being done right now, that's actually completed enrollment, we'll hopefully see the results very soon. So, there is an emerging thought that instead of intensifying treatment for all patients with EGFR, there may be a population that may be just fine with frontline osimertinib monotherapy and introducing the intensification strategy at the time of emergence of MRD or progression on ctDNA before radiographic progression. So, there are a lot of adaptive molecular response criteria that we are kind of exploring in clinical trials that could inform how the future is going to look like for EGFR and other perhaps targeted therapies as well. So, it's fascinating, and I think there's a lot of opportunity there. Dr. Monty Pal: You know, you asked for my perspective. I actually think that what you highlighted there is the most interesting opportunity for ctDNA: the ability to de-escalate therapy. In terms of drug development, we've done so much to bring new therapies to patients, and now it's a bit of an embarrassment of riches, but the downside is that I feel like we tend to overtreat a lot of patients in the clinic. So, I definitely view MRD, you know, some of these other ctDNA techniques with methylation and so forth that may not be sort of tumor-dependent or bespoke could be incredibly, incredibly helpful. You touched on sort of the future, right, in this last section here with biomarkers. But give us a sense now in terms of novel drug therapies in the EGFR space. What are you most excited about moving forward in 2026 and beyond? Dr. Vamsi Velcheti: Yeah, I think there's a lot going on in this space, and not just this space, but across lung cancer and others as well. Like looking at the next generation of targets for ADCs. And I think a lot of these have to do with…so far in the drug development space, as you know, the improvements in clinical outcomes has been very incremental. So, we really need to make that big leap. And I think the big leap is not going to come from, in my opinion, from the next ADC, but it's going to come from how we tailor treatments and how we monitor disease better and how do we kind of incorporate the next treatment earlier and not wait for the radiographic progression. So, there's a lot of opportunity there to integrate biomarkers and dynamic biomarkers into clinical trial design and incorporating the recent advances in terms of drug design. You know, we have a lot of assets in the EGFR space, the next-generation EGFR inhibitors that are kind of designed with resistance in mind and rational combination, knowing when to introduce those combinations is also equally important. So, there's a lot going on, really exciting times to be in drug development. The one thing that I really hope will come to the forefront in drug development, not just for lung cancer, but all disease groups, is to kind of really be thoughtful about how we incorporate these really cool molecular monitoring tools and creating a composite score with imaging to be able to like really design the next generation of clinical trials. Dr. Monty Pal: You're so spot-on with that. I definitely think that we're getting to this point where, you know, we could think about the next BiTE, the next CAR-T, the next ADC. But, you know, maybe it's time for us to start really honing in on appropriate applications of these drugs, honing in on the right dose and what have you, because I definitely see some issues there.  Vamsi, this has just been terrific. I really want to thank you so much for sharing your fantastic insights with us today on the ASCO Daily News Podcast, and I really appreciate all your efforts to move the field of lung cancer forward. Dr. Vamsi Velcheti: Thanks, Monty. I really enjoyed the conversation. Dr. Monty Pal: Yeah, this was terrific.  And thanks to our listeners as well. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Monty Pal   @montypal  Dr. Vamsi Velcheti @VamsiVelcheti Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Vamsi Velcheti:   Honoraria: Galvanize Therapeutics  Consulting or Advisory Role: Bristol-Myers Squibb, Merck, AstraZeneca/MedImmune, GSK, Amgen, Taiho Oncology, Novocure, Regeneron, Takeda, Janssen Oncology, Picture Health Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline

Rector's Forum from 3/15/2026 at Church of Our Saviour in Jacksonville, FL.

In this special Joint episode Andy Jabbour and Toni Pepper connect at the 6th Annual Cybersecurity Summit in Jacksonville, Florida to talk Tribal-ISAC, key insights and takeaways, and other fun conversations along the way.

Andy and Brendan went LIVE on YouTube following the conclusion of the 2026 Players Championship, recapping an electric Sunday back nine that ended in Cameron Young's second PGA Tour victory. The two initially give some credit to "The Boys" after a week full of adversity in the AirBNB but came with the trade off of a big win for Mr. 1,000. Young defeated Matt Fitzpatrick following a blow up from 54-hole leader Ludvig Åberg. Despite a sleepy Saturday and a slow start to Sunday, the last 90 minutes at TPC Sawgrass delivered for viewers once again. Andy and Brendan discuss Cameron Young's history as a "big game player" and how the setup with long rough helped him as a longer hitter off the tee. They also unpack Åberg's collapse on holes 11 and 12 and his gameplan that ended up getting him in trouble. Grades are given to Cam, Ludvig, Scottie Scheffler, the course setup, NBC, and other contenders as is tradition at a "major" event. The Boys, Joseph LaMagna and PJ, join in for the back half of this episode to celebrate a Victory Monday for the only recurring guest in "Lunch with The Boys" history. PJ shares insight from his weekend on the ground and his time following the NYGC tandem of Young and Fitzpatrick on Sunday, while Joseph shines some light on Sudarshan Yellamaraju, one of the breakout players of this week. We wrap with some small unsubstantiated rumors after a successful week in Jacksonville for the 2026 Players Championship. Thank you to ⁠⁠⁠Optum⁠⁠⁠ for their support of our Players Championship coverage.

In Matthew 7, Jesus brings the Sermon on the Mount to a powerful close by confronting one of the most important questions a person can ask: How do you know if you're saved?  This message is a clear call to reject false assurance, religious performance and self-righteousness, and instead put your full trust in Jesus. Salvation is not built on what we do for God, but on what Christ has already done for us. This sermon invites us to stop building on the sinking sand of this world and stand firmly on the unshakable rock of the gospel.

In this throwback episode, we continue our revisit of H.B.'s 2023 conversation with Clinton D. McFarland, founding Pastor of the Grace Bible Church in Stockbridge, Georgia.Get a new website, unlimited custom graphics, & full-service podcast production services at https://IncreaseCreative.Co/HBSubscribe to the Cutting It Straight magazine at https://CISmag.orgConnect with H.B. and access more resources at https://HBCharlesJr.comThe On Preaching Podcast is dedicated to helping you to preach faithfully, clearly, and better.Hosted by H.B. Charles, Jr., Pastor-Teacher of Shiloh.Church in Jacksonville, FloridaProduced by Luke Clayton and the team at IncreaseCreative.Co

Sermon from 3/15/2026 at Church of Our Saviour in Jacksonville, FL.

Willow White joins Larry Blustein to talk about going to the queen of the mat in Lakeland, Florida, and she also talks about her plans for the College Wrestling. She talks about how she wants to land the perfect situation for her when it comes to looking at other colleges. Emily Williams, the head basketball coach of St Thomas Aquinas joins Larry Blustein to talk about the girls' basketball state championship games this past weekend. Geo Millian joins Larry Blustein to talk about the latest going on with the Miami Hurricanes football team as spring practice will open up soon. Joe Blasucci of Pembroke Pines Somerset Academy joins Larry Blustein to talk about the wrestling program he's been building. He talks about the upcoming class that's coming next season for wrestling. Nick LaSala, the head Coach from Boca Raton Spanish River, joins Larry Blustein to talk about having this year's senior class going out as champions. He talks about having Louisville Cardinals Head Coach Jeff Brohm come down to talk about the program, how special it is to join a program that doesn't have a winning history. Head Coach Dave Roca of Pembroke Pines Charter joins Larry Blustein to talk about their state title matchup vs Fleming up in Jacksonville. Dave Roca talks about the program he's built.

Head Coach Dave Roca of Pembroke Pines Charter joins Larry Blustein to talk about their state title matchup vs Fleming up in Jacksonville. Dave Roca talks about the program he's built.

OUTLORE ARCHIVES: The USA, 2003. A serial killer has finally been caught. His name is Paul Durousseau and he'll become known as the Jacksonville Strangler. He's a taxi driver, responsible for the horrifying murders of multiple young women.But once arrested, it seems Paul's murder spree hadn't been limited to the US, instead, there was a potential trail, crossing the ocean, landing in Germany.Resources:https://linktr.ee/eleanornealeresourcesWatch OUTLORE Podcast:https://www.youtube.com/@EleanorNealeFollow Me Here for Updates & Short Form Content:InstagramTikTok

Weekly Message from Maranatha Church of Jacksonville. Find out more at maranathajax.com

Derek Brown of FantasyPros joins Perspectives to talk with JJ about free agency and this year’s draft class. The two discuss the Jacksonville backfield, Kenneth Walker’s outlook in Kansas City, the top of the wide receiver class, and much more. Make sure to check out LateRound.com to preorder the 2026 Late-Round Prospect Guide. Want to get dynasty rankings while accessing the amazing Late-Round community on Discord? Become a Late-Round member today.See omnystudio.com/listener for privacy information.

Heath Cummings is joined by Ben Gretch to break down the latest in NFL free agency and how it could affect your Dynasty team. From Kyler to the Vikings to Chris Rodriguez to Jacksonville, they'll break it all down. Plus...is anyone unsigned going to matter next year? (0:00) Intro & Welcome back Ben Gretch! (1:12) Strategy wise, what is the biggest mistake you see people making in Fantasy Football? (5:37) Are there any advanced stats or analysis being overlooked by most Fantasy managers? (9:56) Do you buy the Daniel Jones and Colts offense we saw last year before he got hurt? (15:49) Kyler to the Vikings: Is it a wide-open QB competition? (24:47) Chris Rodriguez to Jacksonville & Bhayshul Tuten hype (32:12) Rachaad White to the Commanders (& How it affects Jacory Croskey-Merritt) (37:18) Is there anyone unsigned that is actually going to matter next year? (39:27) Depth at tight end (44:04) How do coordinators impact TE play? (46:04) Running Backs being more reliable than wide receivers (53:47) Chat Questions To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Friday's Drill made stops in New Orleans, Las Vegas, and Jacksonville! Plus SKC's Jake Davis joins the show!See omnystudio.com/listener for privacy information.

After several weeks of endless Top 20 matchups, this week feels a bit like a breather as a good number of leagues get into conference play. D-Fly & Dixie are back to get you prepared for all the action.Mr. Lax904 himself, Ray Carnicelli, joins the show as this week's guest analyst. Carnicelli has been a vocal advocate of lacrosse in north Florida for more than three decades and is the play-by-play announcer for Jacksonville University and Flagler College. He shares his experiences helping to grow the game in greater Jacksonville and sits in on the game previews and the Give & Go.Harvard star midfielder Logan Ip sits down with D-Fly as the No. 4-ranked Crimson get set to take on No. 16 Penn in the Ivy opener for both teams. Ip discusses Harvard's fast start, the team leadership, Jordan Field, standout players for Harvard, international lacrosse, the Burrito Bowl, preparing for Penn and much, much more.GAME PREVIEWSALL GAMES SATURDAYNo. 14 Army (6-1, 1-1 Patriot) at Boston U. (4-2, 2-0) | noon | ESPN+ | Army -1.5/22.5Navy (5-2) at No. 12 Johns Hopkins (4-2) | 1 p.m. | ESPN+/ESPNU | JHU -2.5/23.5No. 4 Harvard (5-0) at No. 16 Penn (3-3) | 1 p.m. | ESPN+ | Harvard -2.5/23.5Virginia (3-3) at No. 10 Maryland (2-3) | 1 p.m. | B1G | Maryland -3.5/22.5No. 5 North Carolina (6-1) vs. No. 9 Penn State (4-2) | 6:30 p.m. | Corrigan Sports Network | UNC -1.5/26.5 GIVE & GOIn this week's NFL-themed Give & Go, the guys share thoughts on the recent NFL player movement and discuss the worst free agency moves and trades in league history.

Patrick Daugherty (@RotoPat), Denny Carter and Kyle Dvorchak (@kyletweetshere) break down a newsy “second wave” of free agency, beginning with Daniel Jones’ official return to the Colts. Do we at least like this move in fantasy football? Next, they dig under the hood at running back, debating the signings of Tyler Allgeier, Kenneth Gainwell, Rachaad White and much more. That includes Chris Rodriguez’s fit in Jacksonville, J.K. Dobbins’ return to Denver, and Keaton Mitchell’s Chargers arrival. Along the way they also find time to talk about Isaiah Likely and Chig Okonkwo’s new homes. (2:00) – Pat, Denny, and Kyle deconstruct the curious cancellation of the Ravens trade for Maxx Crosby (8:25) – Top Headlines: Daniel Jones re-ups with Colts, Tyler Allgeier joins Cardinals backfield, Kenneth Gainwell lands with Bucs (26:30) – More RB Moves, Pt 1: Chris Rodriguez links with Jaguars, Rachaad White joins Commanders, J.K. Dobbins returns to Broncos (38:15) – More RB Moves, Pt 2: Keaton Mitchell signs with Chargers, Isiah Pacheco added to Lions (49:20) – TE Free Agency Moves: Isaiah Likely signs with Giants, Chig Okonkwo heads to CommandersSee omnystudio.com/listener for privacy information.

The new league year opens with Foster Moreau and Logan Hall joining the Texans. Marc and John recap the full free agency haul and break down the O-line debate. Marc Vandermeer and John Harris go live from Sports Radio 610 three hours after the new league year officially opens, recapping the complete free agency haul and reacting to the latest additions. The headline signings: tight end Foster Moreau from the Saints joins as the inline blocking tight end the Texans have been seeking — a former LSU number 18 honoree who overcame Hodgkin's lymphoma in 2023 and embodies swarm culture — and defensive lineman Logan Hall arrives from Tampa Bay on a two-year, $14 million deal, bringing first-round pedigree and inside-outside versatility that John compares to Denico Autry's role. The Texans also add defensive end Dominique Robinson from the Bears on a one-year, $4 million deal and re-sign Naquan Jones. John provides the analytical framework for the Moreau signing, breaking down tight end archetypes — inline/wide tight ends (hand in the dirt blockers), F tight ends (receiving specialists like Mike Gesicki), H-backs, and U tight ends (do-it-all hybrids) — and explains why Moreau's ability to win at the point of attack against a six-technique defensive end unlocks the entire running game by threatening the edge and forcing linebackers to flow over the top instead of sitting in gaps. Marc connects the dots across the full free agency period, arguing the Texans have systematically addressed every area fans and analysts identified as needs: running back (Montgomery), offensive line (Ingram, Brown, Braden Smith), safety (Blankenship), tight end (Moreau), defensive line depth (Hall, Robinson, Naquan Jones, Sheldon Rankins return), and special teams (Hummel) — all without a single budget-breaking deal. The offensive line debate continues with the Braden Smith guard-or-tackle question still unresolved, and both hosts argue it won't matter until OTAs at the earliest. Marc draws the Tytus Howard parallel — Howard successfully moved from tackle to guard and held up well — and suggests Smith's college guard background and elite run-blocking ability could open up two positions instead of one if he slides inside. The show closes with an AFC South check-in: the Colts signed Daniel Jones to a two-year, $88 million deal but haven't impressed otherwise, Jacksonville is losing pieces but retains a solid defensive core, and the Titans under Robert Saleh are the dark horse that could start causing problems if Cam Ward takes a step forward.See omnystudio.com/listener for privacy information.

00:00 – 12:29 – Colts sign Daniel Jones, how have they done in free agency so far?, IU falls to Northwestern in the Big Ten Tournament 12:30 – 23:42 – Morning Checkdown 23:43 – 43:37 – The Maxx Crosby trade fallout, Trey Hendrickson lands in Baltimore, do the Colts have any options left for an impactful edge rusher, it sure doesn’t seem like the Colts have gotten better in any area since last season, Alec Pierce talks about the importance of Daniel Jones coming back, IU loses to Northwestern, will they make the tournament, can Purdue top Northwestern today? 43:38 – 1:08:18– Daniel Jones will speak today, why Kevin likes the Jones contract, where is money left for the Colts to spend, IU falls on their face against Northwestern and now await their fate for the tournament, who wins first: IU against Northwestern or Colts winning at Jacksonville, Morning Checkdown 1:08:19 – 1:18:06– Musical playlists, what is the market for Anthony Richardson, where will Kyler Murray end up? 1:18:07 – 1:25:10 – Which team is having the best free agency period, are the Colts going to be okay having missed out on Trey Hendrickson? 1:25:11 – 1:54:53 – The new Colts defensive ends, Nick Cross heads to the Commanders, Big Ten Network’s Bruce Weber joins us to discuss the Big Ten Tournament to this point, is it harder or easier to build teams in the NIL era, how he would handle coaching in this era, his basketball camp back in the day, the Big Ten team he trusts the most aside from Michigan, Morning Checkdown 1:54:53 – 2:06:29 – Daniel Jones will speak today, will he say anything of note?, we play I GOTTA KNOW: Grade for the Colts so far in the off-season, Maxx Crosby’s 2026 team, the sanctity of the NBA Draft Lottery 2:06:30 – 2:09:26 – Can Purdue avoid an upset against Northwestern tonight?, Pacers return home tonightSupport the show: https://1075thefan.com/the-wake-up-call-1075-the-fan/See omnystudio.com/listener for privacy information.

A coalition of community activists say it's high time to turn Jacksonville's Neighborhood Bill of Rights from a promise to a reality.

On this episode, we're discussing the national wrestling promotion “Ring Of Honor” coming to Jacksonville permanently. The promotion is now using the studio at WJCT TV in downtown. Ring Of Honor is owned by Tony Khan, son of Jaguars owner Shad Khan. Khan purchased ROH in 2022 after already owning All Elite Wrestling (AEW). Learn more about your ad choices. Visit megaphone.fm/adchoices

Jacksonville might be shopping the wide receiver as we approach the NFL Draft. Is Washington a fit?

Daniel Hastings is the owner of Jacksonville's newest comic shop in town: Black Cat Comics, and having just celebrated the shop's first anniversary, Dan sits down with us to pull back the curtain on his first 365 days in business. We talked about the challenges and rewards of being a first year comic shop owner, and Jacksonville's rich comic shop history. Dan also breaks down the current state of the industry—discussing the best-selling books of 2025 vs. now, the impact of the speculator bubble, and the surprising resurgence of physical media in the digital age, as well as the sleeper comics everyone should have on their pull listWatch the uncut video version of this episode on YouTubeEnter in the giveaway contest for a 1:1 Absolute Batman sketch cover: HERELINKS: Join our Patreon Community, and get access to bonus episodes, free comics, and other rewards! Try a FREE 7-day trial: HERETake your comic shopping experience to the limit, by shopping online at Gotham City Limit!The Schiller Kessler Group Click here to text us Fan Mail!Check out Teenage Mutant Ninja Turtles: Battle Nexus, the raddest TMNT event of the decade! Buy your tickets for Collective Con 2026, Northeast Florida's largest pop culture convention: HERE Proudly sponsored by IDW ComicsProudly sponsored by Collective ConProudly sponsored by Gotham City LimitDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showREACH OUT!

This week, Hannah and Barbi welcome back historian, author, attorney, and master storyteller Scott Grant for another fascinating dive into the history of Jacksonville and Northeast Florida. Scott first joined the podcast in Episode 57 to share the remarkable story of the German U-boat attack off Jacksonville Beach during World War II, and this time he returns with even more powerful stories from our region's past.The conversation centers on the history of Axe Handle Saturday, one of the most significant and difficult moments in Jacksonville's Civil Rights history. Scott walks through the events leading up to that day, the impact it had on the city, and the broader context of the Civil Rights movement locally.Along the way, they explore the story of Schoolhouse Number Four, discuss the legacy of Gene Ribault, and travel even further back in time to figures like Pedro Menéndez and Dominique de Gourgues, whose actions helped shape the early history of Florida.It's a captivating episode filled with powerful history, surprising connections, and the kind of storytelling that brings the past vividly to life.

What kind of legacy are you building? It's easy to think of legacy as something far in the future, yet the choices we make today are already shaping the tomorrows of our families, our churches, and those who will follow after us. The quiet acts of faithfulness, the priorities we set, and the lives we influence today will echo far beyond what we can see.In this special episode, we pause the When War Comes series to share a meaningful session from last year's North Florida Baptist Ladies Conference held at Immanuel Baptist Church in Jacksonville, Florida. The message challenges us to consider how our daily faithfulness today prepares the way for the generations that follow. As you listen, we also invite you to join us for this year's conference on April 10–11, where women gather for encouragement, fellowship, and spiritual growth.CLICK HERE TO LEARN MORE AND TO REGISTER!If you know of someone who can be helped by listening to the Abundant Living Podcast, please share this episode with them. Please let us know what you think by rating and reviewing this podcast in your podcasting app! We love hearing from our listeners, whether through comments on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠our Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠or messaging us on our website, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠christianladiesfellowship.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. You may also apply to be a part of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠our private Facebook group⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, but be sure to answer all the questions and agree to the group rules when you click to join.You can also email Tracie directly at tburns@immanueljax.org. Thank you for being part of this uplifting and encouraging community of ladies who want to live abundantly for the Lord!

The biggest week in golf outside the majors is here, and we're diving headfirst into everything happening at TPC Sawgrass. On Episode 89 of The Swoosh Life Podcast, we preview The Players Championship from Jacksonville, Florida and break down all the storylines surrounding one of the most iconic stops on the PGA Tour.We kick things off with the world No. 1 Scottie Scheffler and the chatter around his so-called “mini slump.” Is it actually a concern, or just the absurdly high standard he's set for himself? From there we get into Brooks Koepka being asked once again if The Players should be considered the “5th major,” and what that debate really means in today's era of professional golf.We also talk about Tom Kim's electric hole-in-one moment at TGL, the fashion scene popping up in pro shops during these massive tour events, and of course we had to react to the new Players NRG shoe drop from Nike Golf.To close things out, we put our reputations on the line with our Winner's Circle picks — who we think will survive Pete Dye's masterpiece and lift the trophy at Sawgrass this Sunday.The island green is calling. Let's get into it.

Mike and Charlie discussed the latest news from NFL free agency, highlighting the Saints' signings and the Ravens' decision to rescind the Maxx Crosby blockbuster trade. Mike DiRocco, a Jaguars reporter for ESPN, joined Sports Talk. DiRocco broke down what New Orleans is getting in former Jacksonville RB Travis Etienne Jr. He dismissed the rumors surrounding Brian Thomas Jr.'s future in Jacksonville and explained the Jaguars' decision to move on from LB Devin Lloyd.

Mike DiRocco, a Jaguars reporter for ESPN, joined Sports Talk. DiRocco broke down what New Orleans is getting in former Jacksonville RB Travis Etienne Jr. He dismissed the rumors surrounding Brian Thomas Jr.'s future in Jacksonville and explained the Jaguars' decision to move on from LB Devin Lloyd.

Greg Newsome gives the Giants low-cost upside at corner, but the tradeoff is obvious: if his confidence and play have really fallen off, the Giants may still not have solved one of their biggest problems. Patrick Ricard makes the offense tougher and Jason Sanders gives them a veteran answer at kicker, but did the Giants truly get better on Day 2, or did they mostly add role pieces while bigger holes still remain?Follow on Spotify and leave a 5-star review on Apple if you enjoy the show. It helps more Giants fans find the show and keeps the Goofball Army growing.In this episode, Drew and Rob break down the Giants' second day of legal tampering and why the Greg Newsome move became the biggest debate of the show. The talent is real, the age still works, and the price is not crushing, but the concern is obvious too: Newsome looked like a rising player early in his career, then injuries, inconsistency, and lost confidence seemed to knock him off track. If the Giants are getting the old Greg Newsome, this looks like a smart one-year prove-it bet. If they are getting the player Jacksonville benched, then this was a move made because the Giants felt pressure to add any corner at all.The show also gets into why Jason Sanders could quietly end one of the most frustrating problems this team has had for a while. If he is healthy, the Giants may have upgraded a major weakness with one move. Then there is Patrick Ricard, and that signing may be the clearest clue yet about what John Harbaugh wants this offense to become. Drew and Rob go hard on the idea that this team is building toward a more physical, old-school run identity with tight ends, fullback play, and a ground game designed to punish defenses. Micah McFadden returning also gets covered as a clean value move that keeps options open instead of forcing the Giants into a bigger gamble at linebacker.The episode closes with the Brian Thomas Jr. rumor getting cooled off, the guard conversation still wide open, and the bigger question hanging over everything: are the Giants building smartly, or just patching holes one move at a time? The Newsome signing is the sharpest argument in the episode, and the Ricard move is the most exciting.Merch: https://2giantgoofballs-shop.fourthwall.com/ Support: https://buymeacoffee.com/2giantgoofballs All episodes: https://2giantgoofballs.buzzsprout.com/#Giants #NYGiants #NFLFreeAgencySend a textSupport the show

We are back and ready to give you more fun and excitement on Radio Connection Live! Including: a very cool flashback were featured two different stations with the branding queue both from 2021 into 2022.We also enjoy some current air checks from Jacksonville and have our weekly radio conversation and just one more thing as well!It's going to be a good show, so we hope you will enjoy!

We're recapping a quick Florida weekend that packed in a little bit of everything — live music, Disney Springs dining, dessert experiments, and even a quick outlet stop. The trip kicked off in Jacksonville seeing Justin Furstenfeld of Blue October live at FIVE before heading down to Orlando for a stay at the Drury Inn near Disney Springs. From there, we turned the weekend into a mini Disney Springs food crawl with stops at Pizza Ponte, where we tried the Bun Giorno garlic-cheese pinwheel and the Il Gladiatore pizza, followed by a visit to Salt & Straw to sample several of their wild cereal-inspired ice cream flavors. After another Justin Furstenfeld show at the House of Blues, we wrapped the night with a late dinner at Chicken Guy, trying the five-tender combo with sauces like Chipotle Ranch and Garlic Parmesan. Along the way we share our thoughts on the food, the concert experience, staying at the Drury Inn, and a quick stop at the Vineland outlets before heading home. It's a fun, casual recap episode full of food, music, and a little Disney Springs chaos. Jeremy recently released his new book Still Loud, Now Clear, a music-inspired memoir about sobriety, rebuilding life, and finding clarity after years of chaos. If you've ever felt overwhelmed, stuck, or like you were the only one struggling, this book is a reminder that you're not alone—and that a better soundtrack is possible. Learn more at: stillloudnowclear.com

Ryan Green, of 1010 XL in Jacksonville, joined The Drive to discuss the rumors the Jags could be trading WR Brian Thomas Jr.

Joel Lamp is the Sports Development Manager for the Huntsville/Madison County Convention & Visitors Bureau, where he leads efforts to attract major sporting events and tournaments to the Rocket City. In this role, Joel works with national sports organizations, collegiate conferences, and event promoters to bring competitions to Huntsville that drive tourism, economic impact, and national visibility for the region.Lamp brings more than two decades of experience in sports management, collegiate athletics, and event operations. Before returning to North Alabama, he spent over 16 years in Jacksonville, Florida, where he held senior leadership roles in collegiate athletics at both Jacksonville University and the University of North Florida. During that time, he helped organize and host multiple NCAA Men's Basketball Tournament rounds and numerous regional and national sporting events.Originally from Decatur, Alabama, Joel returned to the Tennessee Valley to help grow Huntsville's rapidly expanding sports tourism industry. Through his work with the Convention & Visitors Bureau and the Huntsville Sports Commission, he has helped position the city as a premier destination for tournaments, championships, and emerging sports events.Joel is passionate about the power of sports to bring communities together, create economic opportunity, and showcase the unique energy and hospitality of Huntsville.Learn more about Joel Lamp and the Convention & Visitors Bureau and Huntsville Sports Commission http://www.huntsville.orgHost/Interviewer: M. Troy Bye, Owner, Our Town with Troy Bye, a brand of the Our Town Company, LLCWatch on YouTube: https://www.youtube.com/channel/UCP5NjTsQ72k00C5n7ghLapAWatch on Spotify:https://open.spotify.com/show/0JwD62zXPncMeFeQdTVomHAudio only available in all other platforms where you get your podcasts.Follow us on social media: LinkedIn: https://www.linkedin.com/in/our-town-w-troy-bye-50033a234/Instagram: https://www.instagram.com/ourtownpodcast/

Sermon from 3/8/2026 at Church of Our Saviour in Jacksonville, FL.

Rector's Forum from 3/8/2026 at Church of Our Saviour in Jacksonville, FL.

Jeff is back with another quick slant instant reaction podcast episode to break down Travis Etienne signing with the New Orleans Saints. Jeff takes a look at what this means for Alvin Kamara's future and what Etienne's outlook is like if Kamara ends up being cut. He then heads to Jacksonville to break down the Jags backfield and Bhayshul Tuten's initial fantasy football outlook. Get Jeff's content: FTN Fantasy Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this throwback episode, we revisit H.B.'s 2023 conversation with Clinton D. McFarland, founding Pastor of the Grace Bible Church in Stockbridge, Georgia.Get a new website, unlimited custom graphics, & full-service podcast production services at https://IncreaseCreative.Co/HBSubscribe to the Cutting It Straight magazine at https://CISmag.orgConnect with H.B. and access more resources at https://HBCharlesJr.comThe On Preaching Podcast is dedicated to helping you to preach faithfully, clearly, and better.Hosted by H.B. Charles, Jr., Pastor-Teacher of Shiloh.Church in Jacksonville, Florida Produced by Luke Clayton and the team at IncreaseCreative.CoSHARE YOUR QUESTIONS, AND IT MAY BE FEATURED IN A FUTURE EPISODE.Drop a comment or go to https://ncrs.cc/opqa to ask your questions.

Jaguars players TE Quintin Morris, LB Dennis Gardeck and CB Montaric Brown speak with the media after re-signing contracts with Jacksonville ahead of the 2026 NFL Season. Jaguars' free agency coverage is presented by Dream Finders Homes.See omnystudio.com/listener for privacy information.

In this episode of 2 Right Turns, we sit down with Kevin Kelly, Clemson's Senior Director of Player Personnel Evaluation with 25 years of NFL scouting experience, to break down the 2026 Clemson draft class, covering players like Blake Miller, T.J. Parker, Antonio Williams, and Cade Klubnik. Later, Jacoby Ford joins to talk about what it means to be back home in Death Valley, this time as an Offensive Player Development coach, reflecting on his legendary playing career and the journey that brought him back to Clemson. Finally, we welcome mid-year enrollee wide receiver Naeem Burroughs for our Freshman Orientation series, as the Jacksonville, Fla., native shares why he chose Clemson, the brotherhood he's found in the receiver room, and the energy he plans to bring to the field!Watch the full episode at www.ClemsonPlus.com

You're listening to Bardtenders! In this episode of "The Mixing Glass", David Cohen joins us to talk about pursuing passion projects, starting a craft distillery, and how to bring Dungeons & Dragons to life inside a glass of whiskey.  ------------David Cohen is currently the COO for Find Familiar Spirits. David is also the President and Head Distiller at Manifest Distilling in Jacksonville, Florida, and is responsible for the day-to-day operations at the distillery. Manifest opened in 2015 and its products are currently distributed in Florida, Georgia, South Carolina and Tennessee, as well as nationwide through online retailers. Most recently, Find Familiar Spirits and Manifest Distilling have opened a joint venture, Expansion Packaging, which is a full-service liquid development and co-pack facility, of which David operates as the President. David also serves as President of the Florida Craft Spirits Association, the first industry supported non-profit established to promote the craft spirits industry throughout the state. His long family history in hospitality began in the early 1940s in the Caribbean, so his involvement in the spirits industry was a natural progression. Prior to founding Manifest, David completed an internship with Kentucky Artisan Distillers and earned a certificate from The Siebel Institute of Technology for Craft Distilling and Operation.Before that, David was responsible for opening or operating several companies ranging from  a production company in Los Angeles to serving as the Creative Director and Vice President of an editorial and publishing company. He resides in Jacksonville, FL with his wife Nina and three adorable children, Abe, Frankie and Charlie.----------Don't miss out on any of the action!  Head to www.bardtender.com to stay up to date with all of the Bardtender content, find resources for mental and physical well-being, get access to education materials, and check out what all of our bards are up to!Support the show

In this episode of the Bleedin Blue & White Podcast, Corey, Nick, Pete react just hours after the NHL trade deadline and try to process what it means for the Toronto Maple Leafs and the rest of the 2025–2026 season.What starts as a normal episode quickly turns into a mix of frustration, disbelief, and reluctant acceptance as the hosts break down the Leafs' quiet deadline and the tough reality facing the team down the stretch. With a difficult remaining schedule and the possibility of missing the playoffs for the first time in a decade, Corey and Nick talk through the emotions of being a long-time Leafs fan when expectations don't meet reality.Along the way, they debate whether the front office did enough at the deadline, look ahead at the brutal slate of games still to come, and try to decide if there's any realistic path forward this season—or if fans should begin preparing for a disappointing finish.Despite the frustration, the episode still brings the usual mix of humor, sarcasm, and fan therapy that defines the show.The episode closes with a shoutout to Jack and the St. John Fisher Cardinals men's ice hockey as they head to Jacksonville for the national tournament.Another emotional ride for Leafs fans—and another honest conversation about what it means to bleed blue and white.

Are you worshiping God, or are you worshiping a mirror? In this convicting installment of the "Underestimated" series, Erin Almond of Higher Definition Church in Jacksonville explores the modern phenomenon of "American Idols." Drawing from Isaiah 40:17-24, this message challenges the "hustle culture" and curated lifestyles that often lead us to create a God in our own image—one that matches our vibes, politics, and sensibilities without ever offering a challenge.Learn how to identify the digital and social idols we build to maintain comfort and control, and discover why a God you can "topple" is not a God who can save. If you are seeking to move from spiritual hobbyism to a deep, set-apart relationship with Christ, this teaching provides the biblical framework to restore your awe of the One who sits enthroned above the circle of the earth. Join our Jacksonville ministry as we resist the "low definition" life and return the Lord to His rightful place on the throne of our hearts.

What did Jesus really mean when He said, “Judge not”? In Matthew 7, Jesus confronts the judgmental spirit that so easily takes root in our hearts and calls His followers to something better—a life marked by grace, humility, and discernment. In this message, we explore the difference between being judgmental and exercising biblical discernment, why dealing with the “log” in our own eye matters before pointing out the “speck” in someone else's, and how the grace of God transforms the way we see people. Ultimately, Jesus invites us to stop living as critics and start living as people shaped by grace. Through prayer, humility, and surrender to Christ, we can step off the broad road of pride and onto the narrow way that leads to life.

In this episode of Bleav in Rams presented by Fanduel, Erin Coscarelli is joined by NFL Draft analyst Joe Deleone who is fresh off his visit to the NFL Combine in Indianapolis. We break down one of the league's most fascinating front office trends - while most teams flood Indy with decision makers, Les Snead and Sean McVay famously stay away. No hand-timed 40s. No viral workout reactions. Just a skeleton crew focused on medicals while the brain trust stays home grinding film. But why? Because for McVay, Game tape tells the truth. Effort. Instinct. Football IQ. The Rams believe that's where real evaluation happens. And here's the wild part. It's working, right?! We dive into how this deliberate “no-show” strategy has quietly influenced the league, why former assistants like Liam Coen and James Gladstone are following suit in Jacksonville, and how the Rams continue to draft well despite giving up valuable face-to-face intel. Plus, with an influx of offensive coaching talent this offseason, what does that signal about their draft priorities? Best player available or position of need? This episode is about process over hype, what fits the system over 'standard' approaches in LA, and why the Rams might once again zig while the rest of the NFL zags. Join us! Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

This week I'm reading from Shannon Cain's book 'Journey of an Eternal Soul: My Journey Through Past Lives to Spiritual Awakening'  Transcend to a higher plane through this gripping memoir of spiritual discovery. Join me as I recount my profound past life regression journey that forever changed my perspective. Through enthralling sessions with the gifted La Donna Permenter, I accessed secrets from distant times and planets. I lived as a fierce warrior, devoted husband, accused witch, and extraterrestrial from an advanced civilization, recalling intricate details about these vivid past lives. My soul traveled through mystical realms where I encountered spirit guides and my council on the other side. They shed light on karmic patterns and offered guidance to align me with my true path. This experience awakened dormant gifts and abilities within me. The revelations from my soul's journey have already created a monumental spiritual awakening, improving all aspects of my life. But this is only the beginning. The adventure continues as I seek answers to humanity's biggest mysteries. What wisdom lies in the Akashic records? Where do our loved ones go when they pass? What is the meaning of life? Unlock these secrets and more as you join me on this captivating voyage of self-discovery! Bio My name is Shannon Cain, and I'm proof that the universe has a sense of humor. Born into the rolling hills of Kentucky where survival often mattered more than spirituality, I spent decades believing I was broken, weird, and fundamentally flawed. What I didn't understand was that the very experiences that felt like curses were actually preparing me for the greatest adventure of my life. I'm not a professional writer—I barely made it through high school and have always struggled with traditional learning. I'm not a certified therapist or ordained minister. I don't have letters after my name or degrees on my wall. What I do have is a direct line to experiences that transformed not just my understanding of life and death, but my entire relationship with reality itself. After twenty years of marriage to my soulmate and six children who continue to teach me what unconditional love looks like, I thought I had life figured out. I was successful in business, comfortable in my routines, and thoroughly convinced that the strange experiences of my childhood were just imagination running wild. Then the universe decided it was time for me to remember who I really was. This book chronicles that remembering—the past-life regressions that showed me I had lived before and would live again, the communications with deceased relatives that proved love transcends death, the journeys to other dimensions that revealed the magnificent architecture of consciousness itself. I'm sharing this story not because I want attention or credibility, but because I was given a mission: help others understand that the strange experiences they're having aren't signs of mental illness but evidence of awakening. The vivid dreams, the sense of knowing things you've never learned, the feeling that this world isn't quite real—trust those experiences. They're pointing you toward the truth of who you really are. We live in an incredible time when more humans are remembering their spiritual nature than ever before in recorded history. If this book finds its way to you, it's probably no accident. Something in your soul recognizes these truths, even if your logical mind wants to dismiss them. Listen to that recognition. Follow it. Because on the other side of that leap of faith lies a reality more beautiful and interconnected than you ever dared imagine. The whispers are calling you home. All you have to do is listen. Shannon Cain currently lives in Jacksonville, Florida, with his wife and children, where he continues to explore the endless frontier of consciousness while somehow managing to pay the bills and remember to take out the trash. https://www.amazon.com/dp/B0FQJZN5XP   La Donna Permenter I have been driven my entire life with the desire to help people, by working in the medical field I have been able to fulfill that dream. I have spent 35 years in the medical field starting in the EMS services, then 25 (+) years in Pulmonary and Infectious Disease working with a wonderful group of doctors at the forefront of HIV-AIDS in the late 80's.  I also spent several years as a clinical manager for a large pain management practice. In 2009, I started my own company in the outpatient mental health field.  I built the practice into a group of 12 Psychotherapists,  including Licensed Mental Health Counselors, Licensed Clinical Social Workers and Psychologists. I enjoyed my many years in medicine, and I see now how all of this was also a part of my journey, by experiencing the interactions with all of the beautiful people that were my patients over the years. It was during this time that I realized there had to be another way to expand on the care to assist people further and in a much deeper way.  In medicine we focus on healing the body, but we must not forget to integrate the healing of the body, mind and the Soul. With this desire to expanded and connect at a deeper level, I sold the mental health practice and dedicated myself full time to what I now know is my true calling in life, completely. During many years of research and studying to expand my knowledge on this level of deeper care, I discovered Dolores Cannon's QHHT -Quantum Healing Hypnosis Technique /PLR regression therapy. It was Dolores Cannon that developed the practice of QHHT; she developed this procedure over her 50 years of success, helping others awaken to their life purpose. I realized that this is my calling, and I promptly became a certified dedicated provider. I have spent hundreds of hours of study and practical hands on application throughout the studies of QHHT -Quantum Healing Hypnosis Technique. https://yoursoulrecovery.com/ https://www.pastliveshypnosis.co.uk/https://www.patreon.com/ourparanormalafterlifeMy book 'Verified Near Death Experiences' https://www.amazon.com/dp/B0DXKRGDFP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Brett and Ariya return to recap the weekend against The Citadel. FSU swept the Bulldogs with dominant pitching. The guys discuss the first time the weekend rotation was fully intact, the optimism of the advantage they provide, and why they could be the key to the season. They also touch on the bats going cold, concerning offensive trends, and how the Noles can turn it around at the plate. They finish by previewing a challenging midweek slate against Jacksonville and Mercer coming to Howser.

In Matthew 6, Jesus warns us to beware of practicing our righteousness to be seen by others, reminding us that with God it's not just what we do—it's why we do it.  Giving, praying, and fasting can either be acts of worship or subtle performances for applause, and while we all know we must repent of our wretchedness, Jesus confronts us with the deeper need to repent of religious righteousness rooted in image instead of intimacy. When the Father is our audience, generosity reorders our hearts, prayer becomes communion instead of performance, fasting trains us to say no to our flesh and yes to Jesus, and the true reward isn't recognition—it's Him. 

In this throwback episode, we continue our revisit of H.B.'s 2023 conversation with Steve Gaines, Pastor Emeritus of Bellevue Baptist Church in Memphis, Tennessee. After serving as Senior Pastor for 19 years, Dr. Gaines transitioned to his emeritus role in 2024. He also served as the President of the Southern Baptist Convention from 2016 to 2018. He continues to be a widely respected voice in the areas of prayer, evangelism, and pastoral ministry.Get a new website, unlimited custom graphics, & full-service podcast production services at https://IncreaseCreative.Co/HBSubscribe to the Cutting It Straight magazine at https://CISmag.orgConnect with H.B. and access more resources at https://HBCharlesJr.comThe On Preaching Podcast is dedicated to helping you to preach faithfully, clearly, and better.Hosted by H.B. Charles, Jr., Pastor-Teacher of Shiloh.Church in Jacksonville, Florida Produced by Luke Clayton and the team at IncreaseCreative.Co

This week I'm talking to Shannon Cain about his book 'Journey of an Eternal Soul: My Journey Through Past Lives to Spiritual Awakening' and we are also joined by Past Life Regression practitioner La Donna Permenter. Transcend to a higher plane through this gripping memoir of spiritual discovery. Join me as I recount my profound past life regression journey that forever changed my perspective. Through enthralling sessions with the gifted La Donna Permenter, I accessed secrets from distant times and planets. I lived as a fierce warrior, devoted husband, accused witch, and extraterrestrial from an advanced civilization, recalling intricate details about these vivid past lives. My soul traveled through mystical realms where I encountered spirit guides and my council on the other side. They shed light on karmic patterns and offered guidance to align me with my true path. This experience awakened dormant gifts and abilities within me. The revelations from my soul's journey have already created a monumental spiritual awakening, improving all aspects of my life. But this is only the beginning. The adventure continues as I seek answers to humanity's biggest mysteries. What wisdom lies in the Akashic records? Where do our loved ones go when they pass? What is the meaning of life? Unlock these secrets and more as you join me on this captivating voyage of self-discovery! Bio My name is Shannon Cain, and I'm proof that the universe has a sense of humor. Born into the rolling hills of Kentucky where survival often mattered more than spirituality, I spent decades believing I was broken, weird, and fundamentally flawed. What I didn't understand was that the very experiences that felt like curses were actually preparing me for the greatest adventure of my life. I'm not a professional writer—I barely made it through high school and have always struggled with traditional learning. I'm not a certified therapist or ordained minister. I don't have letters after my name or degrees on my wall. What I do have is a direct line to experiences that transformed not just my understanding of life and death, but my entire relationship with reality itself. After twenty years of marriage to my soulmate and six children who continue to teach me what unconditional love looks like, I thought I had life figured out. I was successful in business, comfortable in my routines, and thoroughly convinced that the strange experiences of my childhood were just imagination running wild. Then the universe decided it was time for me to remember who I really was. This book chronicles that remembering—the past-life regressions that showed me I had lived before and would live again, the communications with deceased relatives that proved love transcends death, the journeys to other dimensions that revealed the magnificent architecture of consciousness itself. I'm sharing this story not because I want attention or credibility, but because I was given a mission: help others understand that the strange experiences they're having aren't signs of mental illness but evidence of awakening. The vivid dreams, the sense of knowing things you've never learned, the feeling that this world isn't quite real—trust those experiences. They're pointing you toward the truth of who you really are. We live in an incredible time when more humans are remembering their spiritual nature than ever before in recorded history. If this book finds its way to you, it's probably no accident. Something in your soul recognizes these truths, even if your logical mind wants to dismiss them. Listen to that recognition. Follow it. Because on the other side of that leap of faith lies a reality more beautiful and interconnected than you ever dared imagine. The whispers are calling you home. All you have to do is listen. Shannon Cain currently lives in Jacksonville, Florida, with his wife and children, where he continues to explore the endless frontier of consciousness while somehow managing to pay the bills and remember to take out the trash. https://www.amazon.com/dp/B0FQJZN5XP La Donna Permenter I have been driven my entire life with the desire to help people, by working in the medical field I have been able to fulfill that dream. I have spent 35 years in the medical field starting in the EMS services, then 25 (+) years in Pulmonary and Infectious Disease working with a wonderful group of doctors at the forefront of HIV-AIDS in the late 80's.  I also spent several years as a clinical manager for a large pain management practice. In 2009, I started my own company in the outpatient mental health field.  I built the practice into a group of 12 Psychotherapists,  including Licensed Mental Health Counselors, Licensed Clinical Social Workers and Psychologists. I enjoyed my many years in medicine, and I see now how all of this was also a part of my journey, by experiencing the interactions with all of the beautiful people that were my patients over the years. It was during this time that I realized there had to be another way to expand on the care to assist people further and in a much deeper way.  In medicine we focus on healing the body, but we must not forget to integrate the healing of the body, mind and the Soul. With this desire to expanded and connect at a deeper level, I sold the mental health practice and dedicated myself full time to what I now know is my true calling in life, completely. During many years of research and studying to expand my knowledge on this level of deeper care, I discovered Dolores Cannon's QHHT -Quantum Healing Hypnosis Technique /PLR regression therapy. It was Dolores Cannon that developed the practice of QHHT; she developed this procedure over her 50 years of success, helping others awaken to their life purpose. I realized that this is my calling, and I promptly became a certified dedicated provider. I have spent hundreds of hours of study and practical hands on application throughout the studies of QHHT -Quantum Healing Hypnosis Technique. https://yoursoulrecovery.com/ https://www.pastliveshypnosis.co.uk/https://www.patreon.com/ourparanormalafterlifeMy book 'Verified Near Death Experiences' https://www.amazon.com/dp/B0DXKRGDFP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.